GDC-0084 clinical trials
Also written GDC-0084 and Paxalisib.
How each study uses GDC-0084 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GDC-0084 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 9
Kazia Therapeutics Limited (2) · Memorial Sloan Kettering Cancer Center (1) · Weill Medical College of Cornell University (1) · St. Jude Children's Research Hospital (1) · Genentech, Inc. (1) · Sabine Mueller, MD, PhD (1) · Global Coalition for Adaptive Research (1) · Sovargen (1)
Often tested with
Tested in the same studies.
Temozolomide (2) · Metformin (1) · Gemcitabine (1) · Regorafenib (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1) · Troriluzole (1) · Pegargiminase (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test GDC-0084.
- Dec 2026GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal MetastasesPhase 1 · Memorial Sloan Kettering Cancer Center
- Dec 2026Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLPhase 2 · Lakshmi Nayak, MD
- Feb 2027Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)Phase 1/2 · Sovargen
Studies
Open first, then newest update. How each study uses GDC-0084 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)RecruitingPhase 2Sabine Mueller, MD, PhDNCT07447076Written as Paxalisib
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as Paxalisib
- Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)RecruitingPhase 1/2SovargenNCT07287202Written as SVG103
- Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLRecruitingPhase 2Lakshmi Nayak, MDNCT04906096Written as PAXALISIB
- 5G-PEARL: Paxalisib in Malignant Brain TumoursRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT07391215Written as Paxalisib
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingPhase 1/2Australian & New Zealand Children's Haematology/Oncology GroupNCT06208657Written as Paxalisib
- Paxalisib With a High Fat, Low Carb Diet and Metformin for GlioblastomaCompletedPhase 2Weill Medical College of Cornell UniversityNCT05183204Written as Paxalisib
- GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesTerminatedPhase 2Dana-Farber Cancer InstituteNCT03765983Written as GDC-0084
- GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal MetastasesActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT04192981Written as GDC-0084
- Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed GlioblastomaCompletedPhase 2Kazia Therapeutics LimitedNCT03522298Written as Paxalisib (GDC-0084)
- Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male SubjectsCompletedPhase 1Kazia Therapeutics LimitedNCT05012670Written as [14C]-Paxalisib Capsule
- Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline GliomasCompletedPhase 1St. Jude Children's Research HospitalNCT03696355Written as GDC-0084
- A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade GliomaCompletedPhase 1Genentech, Inc.NCT01547546Written as GDC-0084
Given beside what is tested · 1 — GDC-0084 is usual care or a partner of the new treatment
Codes
What other systems call GDC-0084 · ClinicalTrials.gg INT001070
- MeSH (NLM) C000630586GDC-0084Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) P5DKZ70636PAXALISIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630586 | GDC-0084 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P5DKZ70636 | PAXALISIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.